Cargando…

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer

BACKGROUND: Immunotherapy, monotherapy, and immunotherapy plus platinum-based chemotherapy are the standard treatments for advanced non-small cell lung cancer (NSCLC) patients with negative driver genes. However, the impact of similar continuing immunotherapy beyond progression (IBP) of first-line i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Manyi, Hao, Yue, Zeng, Xiaohong, Si, Jinfei, Song, Zhengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183556/ https://www.ncbi.nlm.nih.gov/pubmed/37197488 http://dx.doi.org/10.21037/jtd-22-1611

Ejemplares similares

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma
por: Wei, Jingwen, et al.
Publicado: (2023)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study
por: Tian, Tian, et al.
Publicado: (2022)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
por: Hao, Yue, et al.
Publicado: (2022)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
por: Prelaj, Arsela, et al.
Publicado: (2021)

Cancer immunotherapy: Moving beyond checkpoint inhibition
por: Boes, Marianne
Publicado: (2018)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy
por: Valencia-Sanchez, Cristina, et al.
Publicado: (2021)

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
por: Morshed, Ramin, et al.
Publicado: (2021)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
por: Won, Sang Eun, et al.
Publicado: (2020)

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
por: Wei, Jingwen, et al.
Publicado: (2022)

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer
por: Yu, Xin, et al.
Publicado: (2021)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

Next generation of immune checkpoint inhibitors and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
por: Rajani, Karishma R., et al.
Publicado: (2015)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors
por: Cadena, Alexandra P, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vbmj63vqbvpld4b3klm2895bad